A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)

Cristina Mussini, Franco Maggiolo, Vanni Borghi et al.|PLoS ONE|2019

Cited by 16